Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05525520 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
A Phase 2 study of Pruritus, sponsored by Escient Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
- 20
- Study locations
NCT05525520 is a Phase 2 study of Pruritus that has completed, run by Escient Pharmaceuticals. The registered enrollment target is 62 participants, below the 106-participant average among 12 other Pruritus trials with a reported enrollment target (42% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT05525520, a Phase 2 study of Pruritus, has completed, sponsored by Escient Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase 2 trial will evaluate the effects of EP547 in subjects with cholestatic pruritus due to Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EP547
Study Locations (20)
California
- Southern California Research Center - Coronado
- Science 37 - Culver City
- California Liver Research Institute - Pasadena
Texas
- The Liver Institute at Methodist Dallas Medical Center - Dallas
- Liver Associates of Texas, PA - Houston
- Gastro Health & Nutrition - Katy
Louisiana
- Tulane University Health Sciences Center - New Orleans
- Ochsner Medical Center - New Orleans
New York
- NYU Grossman School of Medicine Gastroenterology and Hepatology - New York
- Montefiore Medical Center - The Bronx
Ohio
- Gastro Health Research - Cincinnati
- University Hospitals Cleveland Medical Center - Cleveland
Alabama
- University of Alabama Birmingham Hospital - Birmingham
Arizona
- Dignity Health Center for Clinical Research at St. Joseph Hospital - Phoenix
Florida
- University of Miami - Schiff Center for Liver Diseases - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2022-10-06 |
| Est. Completion | 2024-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05525520
The ClinicalTrials.gov registry entry for NCT05525520 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 106-participant average among 12 other Pruritus trials with a reported enrollment target (42% lower). The listed sponsor is Escient Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pruritus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05525520 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Texas, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05525520 about?
NCT05525520 is a clinical study titled "Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis". This phase 2 trial will evaluate the effects of EP547 in subjects with cholestatic pruritus due to Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC)
What is the current status of trial NCT05525520?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2022-10-06. Estimated completion is 2024-09-05.
What conditions does trial NCT05525520 study?
This clinical trial studies the following conditions: Pruritus.
What interventions are being tested in trial NCT05525520?
The interventions under investigation include: Placebo (DRUG), EP547 (DRUG).
Who is sponsoring clinical trial NCT05525520?
This trial is sponsored by Escient Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05525520 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pruritus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients
COMPLETED · Phase 2
-
A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis
COMPLETED · Phase 2
-
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
COMPLETED · Phase 2
-
B244 Topical Spray for the Treatment of Pruritus in Adults With a History of Atopic Dermatitis
COMPLETED · Phase 2
-
The Efficacy of 3% Kanuka Oil Versus 1% Hydrocortisone Cream in Patients With Atopic Dermatitis
RECRUITING · NA
-
VR-PMR for Post-Burn Symptoms
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.